Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2006 Oct 24;78(12):1509–1512. doi: 10.1002/jmv.20732

Evaluation of a novel vesicular stomatitis virus pseudotype‐based assay for detection of neutralizing antibody responses to SARS‐CoV

Shuetsu Fukushi 1,✉, Tetsuya Mizutani 1, Masayuki Saijo 1, Ichiro Kurane 1, Fumihiro Taguchi 2, Masato Tashiro 2, Shigeru Morikawa 1
PMCID: PMC7166816  PMID: 17063504

Abstract

Severe acute respiratory syndrome (SARS)‐coronavirus (SARS‐CoV) is the causative agent of SARS. The S protein of SARS‐CoV is a major target for neutralizing antibodies (Nabs) in infected patients. We developed a neutralization assay using a recombinant vesicular stomatitis virus (VSV) bearing SARS‐CoV‐S protein (VSV‐SARS‐St19). A total of 56 serum samples collected from 22 healthcare workers in the Hanoi French Hospital during the SARS epidemic in 2003 were evaluated and compared to the conventional neutralizing assay using infectious SARS‐CoV. The results of the neutralization assay using VSV‐SARS‐St19 pseudotype showed good correlations with those using infectious SARS‐CoV. The newly developed neutralization assay was more sensitive to low antibody titers in serum samples. Thus, the VSV‐SARS‐St19 is a useful tool for detecting Nabs against SARS‐CoV. J. Med. Virol. 78:1509–1512, 2006. © 2006 Wiley‐Liss, Inc.

Keywords: SARS coronavirus, VSV, pseudotype, neutralization

REFERENCES

  1. Fukushi S, Mizutani T, Saijo M, Matsuyama S, Miyajima N, Taguchi F, Itamura S, Kurane I, Morikawa S. 2005. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol 86: 2269–2274. [DOI] [PubMed] [Google Scholar]
  2. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pohlmann S. 2004. Susceptibility to SARS coronavirus S protein‐driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 319: 1216–1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hong TC, Mai QL, Cuong DV, Parida M, Minekawa H, Notomi T, Hasebe F, Morita K. 2004. Development and evaluation of a novel loop‐mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol 42: 1956–1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hourfar MK, Roth WK, Seifried E, Schmidt M. 2004. Comparison of two real‐time quantitative assays for detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol 42: 2094–2100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. 2003. Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450– 454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Nie Y, Wang P, Shi X, Wang G, Chen J, Zheng A, Wang W, Wang Z, Qu X, Luo M, Tan L, Song X, Yin X, Ding M, Deng H. 2004. Highly infectious SARS‐CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem Biophys Res Commun 321: 994–1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ogino M, Ebihara H, Lee BH, Araki K, Lundkvist A, Kawaoka Y, Yoshimatsu K, Arikawa J. 2003. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin Diagn Lab Immunol 10: 154–160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Saijo M, Ogino T, Taguchi F, Fukushi S, Mizutani T, Notomi T, Kanda H, Minekawa H, Matsuyama S, Long HT, Hanh NT, Kurane I, Tashiro M, Morikawa S. 2005. Recombinant nucleocapsid protein‐based IgG enzyme‐linked immunosorbent assay for the serological diagnosis of SARS. J Virol Methods 125: 181–186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. 1997. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 94: 14764–14769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, Weiss RA. 2005. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 11: 411–416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. WHO . 2003. Summary of probable cases with onset of illness from 1 November 2002 to 31 July 2003. World Health Organization.

Articles from Journal of Medical Virology are provided here courtesy of Wiley

RESOURCES